Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Enters distribution agreement with Abcam PLC to sell its recently developed SARS-CoV-2 research Elisa Affimer reagents.
Under the global, non-exclusive distribution agreement, Abcam will enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its online catalogue.
"This will allow scientists around the world to perform the Elisa test in their own laboratories and support the global fight against the pandemic," says Avacta.
Current Avacta stock price: 248.05 pence, up 6.5% on Tuesday
Year-to-date change: more than double 114p at end of 2020
Current Abcam stock price: 1,396.50p, down 1.0% on Tuesday
Year-to-date change: down 10%
By Lucy Heming;Â firstname.lastname@example.org
Copyright 2021 Alliance News Limited. All Rights Reserved.